- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sangamo Therapeutics Inc (SGMO)
Sangamo Therapeutics Inc stock price live, this page displays NASDAQ SGMO stock exchange data. View the SGMO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Sangamo Therapeutics Inc real time stock price chart below.
What Is the Sangamo Therapeutics Inc Stock Price Today?
The Sangamo Therapeutics Inc stock price today is 0.6990.
What Is the Stock Symbol for Sangamo Therapeutics Inc?
The stock symbol for Sangamo Therapeutics Inc is ""SGMO.""
What Stock Exchange Does Sangamo Therapeutics Inc Trade On?
Sangamo Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sangamo Therapeutics Inc a Good Stock to Buy?
Determining whether Sangamo Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SGMO quote. (ISIN: US8006771062)
What Is the Sangamo Therapeutics Inc Stock Price Today?
The Sangamo Therapeutics Inc stock price today is 0.6990.
What Is the Stock Symbol for Sangamo Therapeutics Inc?
The stock symbol for Sangamo Therapeutics Inc is ""SGMO.""
What Stock Exchange Does Sangamo Therapeutics Inc Trade On?
Sangamo Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Sangamo Therapeutics Inc a Good Stock to Buy?
Determining whether Sangamo Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SGMO quote. (ISIN: US8006771062)
NASDAQ
Currency in USD
Fair Value
An estimate of a Sangamo Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.6800
0.7255
52 wk Range
0.4111
3.1790
SGMO Scorecard
Full Analysis
Quickly burning through cash
SGMO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Sangamo Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.68000.7255
52 wk Range
0.41113.1790
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SGMO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Sangamo Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
4.1000
Upside
+486.55%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy
Sangamo Therapeutics Inc Company Profile
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Sangamo Therapeutics Inc SWOT Analysis
Genomic Frontie | Sangamo Therapeutics leads in gene editing with its ZFP technology, advancing treatments for rare genetic disorders like Fabry disease and prion disease |
Financial Tightrope | Despite cash reserves exceeding debt, Sangamo faces a critical period as it races to extend its runway through strategic partnerships and capital raises |
Pipeline Progress | Explore Sangamo's promising developments, including a potential BLA filing for Fabry disease treatment in Q1 2026 and advancements in chronic neuropathic pain |
Market Valuation | Analysts offer mixed views, with price targets ranging from $2 to $9, reflecting the high-risk, high-reward nature of Sangamo's genomic medicine endeavors |
Sangamo Therapeutics Inc Earnings Call Summary for Q2/2025
- Q2 2025 earnings miss: EPS of -$0.08 vs -$0.02 forecast, revenue of $18.3M vs $29.9M expected; stock drops 8.93% in premarket
- Positive results from STAR study in Fabry disease; BLA submission planned for Q1 2026; seeking commercialization partner
- Cash runway expected to fund operations into 2025; financial health score of 1.83 (Fair) with low profitability and cash flow metrics
- STAND trial for chronic neuropathic pain to begin fall 2025; preliminary efficacy data expected in 2026
- Challenges include securing partner, financial sustainability, potential trial delays, and competitive pressures in genomic medicine
Last Updated: 08/08/2025, 11:06
Read Full TranscriptCompare SGMO to Peers and Sector
Metrics to compare | SGMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSGMOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | −2.9x | −0.7x | |
PEG Ratio | −0.04 | −0.09 | 0.00 | |
Price/Book | 10.8x | 2.5x | 2.6x | |
Price / LTM Sales | 2.6x | 10.3x | 3.4x | |
Upside (Analyst Target) | 192.9% | 237.4% | 36.2% | |
Fair Value Upside | Unlock | −2.3% | 4.1% | Unlock |
Analyst Ratings
4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.1000
(+486.55% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.08 / -0.02
Revenue / Forecast
18.30M / 29.90M
People Also Watch
FAQ
What Stock Exchange Does Sangamo Therapeutics Trade On?
Sangamo Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Sangamo Therapeutics?
The stock symbol for Sangamo Therapeutics is "SGMO."
What Is the Sangamo Therapeutics Market Cap?
As of today, Sangamo Therapeutics market cap is 209.81M.
What Is Sangamo Therapeutics's Earnings Per Share (TTM)?
The Sangamo Therapeutics EPS (TTM) is -0.28.
When Is the Next Sangamo Therapeutics Earnings Date?
Sangamo Therapeutics will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is SGMO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Sangamo Therapeutics Stock Split?
Sangamo Therapeutics has split 0 times.
How Many Employees Does Sangamo Therapeutics Have?
Sangamo Therapeutics has 183 employees.
What is the current trading status of Sangamo Therapeutics (SGMO)?
As of 07 Oct 2025, Sangamo Therapeutics (SGMO) is trading at a price of 0.6990, with a previous close of 0.68. The stock has fluctuated within a day range of 0.6800 to 0.7255, while its 52-week range spans from 0.4111 to 3.1790.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.